1 / 9

GAP573 – Novel Peptide Modulator of Cell Communication

Discover GAP573, a novel peptide modulator derived from animal lenses, enhancing cell communication for wound healing. This peptide shows low adverse reaction risks, enters cells easily, and is simple to manufacture for diabetic foot ulcers. With potential applications in diabetic care, the peptide targets inflammatory cell processes, promotes blood vessel formation, and reduces scarring. The technology addresses a critical unmet market need with significant potential in the healthcare industry, offering strategic advantages for commercialization.

amber-bowen
Download Presentation

GAP573 – Novel Peptide Modulator of Cell Communication

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GAP573 – Novel Peptide Modulator of Cell Communication Presenter: Dr Keryn Johnson Senior Research Scientist Industrial Research Limited, NZ k.johnson@irl.cri.nz Contact: Dr Duncan Veal, Commercialisation Manager, Meat and Livestock Australia dveal@mla.com.au Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  2. Disclaimer Care is taken to ensure the accuracy of the information contained in this publication. However MLA and IRL cannot accept responsibility for the accuracy or completeness of the information or opinions contained in the publication. You should make your own enquiries before making decisions concerning your interests. MLA and IRL accepts no liability for any losses incurred if you rely solely on this publication concerning your interests. Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  3. Technology – GAP573 Sheep Lens Technology| Our Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174 Discovered in animal lenses MOA - Cell communication Low likelihood of adverse reactions Small peptide enter cells Simple to manufacture short peptide

  4. Application 1 - Wound Healing Diabetic Food Ulcer • 200,000 Australians have foot ulcers • 45,000 Australians have lost a limb • 1000 Australians die each year from complications. • Growing problem • Aging population • Increase in prevalence of chronic disease • Spiralling health care costs Unmet Market Need | Our Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  5. The Solution Inhibition of Gap junction communication GAP573 in alginate gel GAP573 proposed binding to ZO Unmet Market Need | The Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  6. Inflammatory cell staining CD68 -macrophage Pig wound healing pilot study Stimulation of blood vessel formation Rat wound healing closure rate Gap573 Control GAP573 Preclinical Studies Unmet Market Need | Our Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  7. Market Size [1] Drug-device Combinations: The Global Market Report Code: PHM045B Published: January 2010 BCC research Unmet Market Need | Our Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  8. Competitive Edge Unmet Market Need | Our Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

  9. GAP573 Summary • Strategic partner to commercialise GAP573 a modulator of gap junction communication • Accelerates wound healing • Reduces inflammation • Promotes blood vessel formation (angiogenesis) • Reduces scaring • Patented technology (2 families) • Significant market need Unmet Market Need | Our Solution | Development Status | Market Size | Competitive Edge| Summary Dr Keryn Johnson k.johnson@irl.cri.nz Mobile: +64 (0) 212941174

More Related